Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

Dolan, Mary

One or more keywords matched the following properties of Dolan, Mary

Property	Value
keywords	Neuropathy, Peripheral
overview	The Dolan lab is focused on improving the quality of life of cancer patients through the identification of genetic variants associated with risk for severe and persistent toxicities following chemotherapy (i.e. peripheral neuropathy, ototoxicity, tinnitus), particularly in children and young adults whose adverse sequelae could persist throughout their lifetimes. To this end, they perform clinical genome wide association studies (GWAS) to identify genetic variants associated with toxicity in patients following chemotherapy and determine whether there is shared genetic architecture with idiopathic forms of these traits. They develop preclinical models to elucidate the biochemical and cellular impact of genes identified in clinical GWAS of chemotherapeutic toxicity. Their approach integrates multiple large datasets including: genetic variation, gene expression, miRNA, modified cytosine, transcription factor levels and chemotherapeutic induced pharmacologic traits. Her laboratory made the seminal observation that chemotherapeutic-induced cytotoxicity is a heritable trait and that pharmacologic SNPs, identified through GWAS, are enriched in expression quantitative trait loci. Her laboratory has developed an induced pluripotent stem cell derived neuronal cell model to evaluate genes contributing to chemotherapeutic-induced neuropathy, a common adverse event of multiple chemotherapeutic agents. The models they are developing will have broad applicability for gaining insight on druggable targets to treat or prevent this devastating side effect of chemotherapy and providing an understanding of the genetic components and genes contributing to severe toxicity. Her laboratory is using machine learning to build predictive models for identifying patients at greatest risk for severe toxicities.

Property

Value

keywords

Neuropathy, Peripheral

overview

The Dolan lab is focused on improving the quality of life of cancer patients through the identification of genetic variants associated with risk for severe and persistent toxicities following chemotherapy (i.e. peripheral neuropathy, ototoxicity, tinnitus), particularly in children and young adults whose adverse sequelae could persist throughout their lifetimes. To this end, they perform clinical genome wide association studies (GWAS) to identify genetic variants associated with toxicity in patients following chemotherapy and determine whether there is shared genetic architecture with idiopathic forms of these traits. They develop preclinical models to elucidate the biochemical and cellular impact of genes identified in clinical GWAS of chemotherapeutic toxicity. Their approach integrates multiple large datasets including: genetic variation, gene expression, miRNA, modified cytosine, transcription factor levels and chemotherapeutic induced pharmacologic traits. Her laboratory made the seminal observation that chemotherapeutic-induced cytotoxicity is a heritable trait and that pharmacologic SNPs, identified through GWAS, are enriched in expression quantitative trait loci. Her laboratory has developed an induced pluripotent stem cell derived neuronal cell model to evaluate genes contributing to chemotherapeutic-induced neuropathy, a common adverse event of multiple chemotherapeutic agents. The models they are developing will have broad applicability for gaining insight on druggable targets to treat or prevent this devastating side effect of chemotherapy and providing an understanding of the genetic components and genes contributing to severe toxicity. Her laboratory is using machine learning to build predictive models for identifying patients at greatest risk for severe toxicities.

One or more keywords matched the following items that are connected to Dolan, Mary

Item Type	Name
Concept	Peripheral Nervous System Diseases
Academic Article	Regulatory polymorphisms in ß-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.
Academic Article	Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
Academic Article	Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
Academic Article	Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.
Academic Article	Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy.
Academic Article	Chemotherapy-induced peripheral neuropathy: Current status and progress.
Academic Article	Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.
Academic Article	Application of stem cell derived neuronal cells to evaluate neurotoxic chemotherapy.
Academic Article	Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine.
Academic Article	Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy.
Grant	Modeling Vincristine-Induced Severe and Persistent Neuropathy
Academic Article	Peripheral neuropathy in children and adolescents treated for cancer.

Search Criteria

Peripheral Nervous System Diseases